Araris, a Swiss oncology biotech company, officially announced in a press release that it has entered into a definitive agreement according to which Taiho Pharmaceutical Co., Ltd. will fully acquire Araris. It is expected that the acquisition will be completed in the first half of 2025. Taiho is a subsidiary of Otsuka Holdings Co., Ltd. and focuses on the fields of oncology and immune-related diseases. According to the agreement, the Japanese company will pay USD 400 million at closing, with additional milestone payments potentially totalling up to USD 740 million. Thus, within only six years after its foundation, Araris reaches the so-called unicorn status (i.e. privately owned startup company valued at over USD 1 billion).
VOSSIUS has been advising Araris for many years, managing their entire IP portfolio both operationally and strategically. Over several months, a VOSSIUS team led by Dr. Philipp Marchand and Dr. sc. ETH Tilmann Künzl supported Araris in the IP due diligence process and contract negotiations on IP issues. VOSSIUS will continue to develop the IP portfolio of the company.
For more information, please read the full ⇢ press release.